Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001641172-25-005633
Filing Date
2025-04-22
Accepted
2025-04-22 09:30:12
Documents
18
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 formdef14a.htm   iXBRL DEF 14A 692586
2 formpre14a_001.jpg GRAPHIC 14249
3 chart_001.jpg GRAPHIC 43629
4 chart_002.jpg GRAPHIC 41307
  Complete submission text file 0001641172-25-005633.txt   1583811

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE lpcn-20241231.xsd EX-101.SCH 5614
6 XBRL DEFINITION FILE lpcn-20241231_def.xml EX-101.DEF 9792
7 XBRL LABEL FILE lpcn-20241231_lab.xml EX-101.LAB 63430
8 XBRL PRESENTATION FILE lpcn-20241231_pre.xml EX-101.PRE 44751
20 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 152799
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36357 | Film No.: 25855848
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)